Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as SERA and PARK. With a market capitalization of $51.98M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against SERA's -320.00% and PARK's 3.43%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
